news
“Untreatable” cases of cystic fibrosis may be undermined by new therapy
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
List view / Grid view
Hit-to-Lead
webinar
Utilising synthetic DNA technologies for high-throughput antibody discovery and optimisation
28 July 2021 | By Sartorius AG
In this on-demand webinar, our expert illustrates the utility of GPCR libraries and explains how to discover potent functional antibodies against multiple GPCR targets.
news
Novel group of small molecules show promise against SARS-CoV-2
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
news
Microcrystal electron diffraction could advance drug development
UK researchers have shown how microcrystal electron diffraction (MicroED) could obtain the structures of potential pharmaceuticals.
webinar
Scalable solutions for automated sample preparation in label-free compound profiling
14 July 2021 | By Analytik Jena
In this on-demand webinar, based on field experiences with our research partners, Analytik Jena provides an overview of application demands for a reliable sample preparation automation – from a small and easy-to-use workstation, to a fully automated integration solution by Analytik Jena.
news
Screening method finds potential drugs to repurpose against COVID-19
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
whitepaper
Brochure: Viral research solutions
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
article
The use of biophysical methods in the hit-to-lead process
Optimisation of a hit towards a lead happens in a variety of ways, as a lead needs to meet various criteria such as activity, affinity to the target, selectivity, solubility, permeability or metabolic stability to become a promising candidate. A balance between in vitro profiles and pharmacokinetic attributes has to…
article
Drug Target Review – Issue 2 2021
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
whitepaper
Brochure: Neuroscience solutions
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
news
Senolytic drugs reduce COVID-19 symptoms in mice, study shows
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
news
Molecules from resin combat epileptic seizures in pre-clinical studies
Drug molecules from pine and spruce trees can affect certain ion channels and had antiseizure effects in pre-clinical studies.
news
Screening identifies existing drugs as potential COVID-19 therapies
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
news
TEMPOL drug shows promise as antiviral treatment for COVID-19
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
whitepaper
ebook: How automation makes labs more efficient
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
